Business Context and Reporting Period
This Form 8-K was filed by Xenon Pharmaceuticals Inc. on March 11, 2016. The report discloses the approval of 2015 non-equity incentive plan payments, 2016 base salaries, and stock option grants for the Company's named executive officers by the compensation committee of the board of directors.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- 2015 Non-Equity Incentive Payments: Total payments to named officers were approximately $224,837 USD (converted from CAD).
- 2016 Base Salaries: Total approved base salaries for named officers were approximately $1,096,175 CAD.
- Stock Option Grants: A total of 190,000 options were granted across two tranches (December 18, 2015, and March 11, 2016).
Material Changes
The filing details specific compensation adjustments effective for the 2016 fiscal year, including retroactive base salary increases effective January 1, 2016. It also outlines the vesting schedules for new option grants, which differ based on the grant date (December 2015 vs. March 2016).
Guidance, Outlook, and Management Commentary
Management commentary is limited to the performance goals tied to the 2016 non-equity incentive plan. Key corporate objectives include:
- Achievement of TV-45070 project goals in collaboration with Teva.
- Initiation of a Phase 2 clinical trial for the Genentech Nav1.7 collaboration.
- Completion of a Phase 2 proof-of-concept clinical trial for XEN801 in moderate to severe acne.
- Selection of a development track candidate from the Nav1.6 program for an Investigational New Drug Application filing in the first half of 2017.
- Advancement of the next discovery program into late-stage lead optimization.
- Execution against the capital markets plan and budget management.
No specific financial guidance or risk factors beyond standard operational goals are provided in this filing.
Important Facts for Investors to Verify
- Verify the vesting conditions and exercise prices ($7.69 and $7.49) for the 190,000 stock options granted to executives.
- Confirm the progress of the XEN801 Phase 2 trial and the Nav1.6 program candidate selection as these are tied to executive compensation.
- Review the definitive proxy statement (Schedule 14A) filed on March 30, 2015, for detailed historical executive compensation data referenced in this report.
- Note that 2015 incentive payments were converted from CAD to USD using an average exchange rate of 0.7834.